Literature DB >> 16105494

Approach to antiarrhythmic therapy in patients with ICDs and frequent activations.

Arnold Pinter1, Paul Dorian.   

Abstract

Patients with an implantable defibrillator may require concomitant antiarrhythmic drug therapy to reduce therapy from the device, especially shocks from the device. New evidence suggests that amiodarone, in combination with b-blockade, is the most effective treatment to reduce the frequency of defibrillator therapies, but sotalol and azimilide have also been shown to be effective. Electrical storm is a serious condition that occurs in 20% of patients living with a defibrillator, and its management requires a complex approach to the patient.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16105494     DOI: 10.1007/s11886-005-0092-5

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  35 in total

1.  Long-term comparison of the implantable cardioverter defibrillator versus amiodarone: eleven-year follow-up of a subset of patients in the Canadian Implantable Defibrillator Study (CIDS).

Authors:  Fayez Bokhari; David Newman; Mary Greene; Victoria Korley; Iqwal Mangat; Paul Dorian
Journal:  Circulation       Date:  2004-07-06       Impact factor: 29.690

2.  Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.

Authors:  Arthur J Moss; Wojciech Zareba; W Jackson Hall; Helmut Klein; David J Wilber; David S Cannom; James P Daubert; Steven L Higgins; Mary W Brown; Mark L Andrews
Journal:  N Engl J Med       Date:  2002-03-19       Impact factor: 91.245

3.  Recurrence of symptomatic ventricular arrhythmias in patients with implantable cardioverter defibrillator after the first device therapy: implications for antiarrhythmic therapy and driving restrictions. CARE Group.

Authors:  N A Freedberg; J N Hill; R I Fogel; E N Prystowsky
Journal:  J Am Coll Cardiol       Date:  2001-06-01       Impact factor: 24.094

4.  Prevention of implantable-defibrillator shocks by treatment with sotalol. d,l-Sotalol Implantable Cardioverter-Defibrillator Study Group.

Authors:  A Pacifico; S H Hohnloser; J H Williams; B Tao; S Saksena; P D Henry; E N Prystowsky
Journal:  N Engl J Med       Date:  1999-06-17       Impact factor: 91.245

5.  Electrophysiologic mechanisms of antiarrhythmic efficacy of a sotalol and class Ia drug combination: elimination of reverse use dependence.

Authors:  S D Lee; D Newman; M Ham; P Dorian
Journal:  J Am Coll Cardiol       Date:  1997-01       Impact factor: 24.094

6.  Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator.

Authors:  Paul Dorian; Martin Borggrefe; Hussein R Al-Khalidi; Stefan H Hohnloser; Jose M Brum; Daljit S Tatla; Johannes Brachmann; Robert J Myerburg; David S Cannom; Michael van der Laan; Michael J Holroyde; Igor Singer; Craig M Pratt
Journal:  Circulation       Date:  2004-11-08       Impact factor: 29.690

7.  Effect of implantable defibrillators on arrhythmic events and mortality in the multicenter unsustained tachycardia trial.

Authors:  Kerry L Lee; Gail Hafley; John D Fisher; Michael R Gold; Eric N Prystowsky; Mario Talajic; Mark E Josephson; Douglas L Packer; Alfred E Buxton
Journal:  Circulation       Date:  2002-07-09       Impact factor: 29.690

8.  Effect of sotalol on ventricular fibrillation and defibrillation in humans.

Authors:  P Dorian; D Newman
Journal:  Am J Cardiol       Date:  1993-08-12       Impact factor: 2.778

9.  Efficacy of metoprolol and sotalol in the prevention of recurrences of sustained ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator.

Authors:  Klaus Kettering; Christian Mewis; Volker Dörnberger; Reinhard Vonthein; Ralph F Bosch; Volker Kühlkamp
Journal:  Pacing Clin Electrophysiol       Date:  2002-11       Impact factor: 1.976

10.  Is inappropriate implantable defibrillator shock therapy predictable?

Authors:  Kumaraswamy Nanthakumar; Paul Dorian; Miney Paquette; Mary Greene; Janet Edwards; Denis Heng; James Noble; David Newman
Journal:  J Interv Card Electrophysiol       Date:  2003-06       Impact factor: 1.900

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.